FI110993B - Förfarande för tillverkning av polysakkarid-proteinkonjugat av B-gruppens streptokock typer II och V - Google Patents
Förfarande för tillverkning av polysakkarid-proteinkonjugat av B-gruppens streptokock typer II och V Download PDFInfo
- Publication number
- FI110993B FI110993B FI951412A FI951412A FI110993B FI 110993 B FI110993 B FI 110993B FI 951412 A FI951412 A FI 951412A FI 951412 A FI951412 A FI 951412A FI 110993 B FI110993 B FI 110993B
- Authority
- FI
- Finland
- Prior art keywords
- type
- polysaccharide
- gbs
- vaccine
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/813—Carrier is a saccharide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Claims (6)
1. Förfarande för tillverkning av en antigen konjugatmolekyl av kapselpolysacka-rid av B-gruppens streptokock typ II eller typ V och protein, kännetecknat av att * 5 (a) kapselpolysackarid av B-gruppens streptokock typ II eller typ V oxideras till- räckligt med perjodat för att bilda en aldehydgrupp i tvä eller flera terminala sial-syrarester anslutna tili polysackaridens stam; (b) den oxiderade kapselpolysackariden av B-gruppens streptokock typ II eller typ V ansluts tili ett protein via reducerande aminering för att ästadkomma en sekundär 10 aminbindning mellan kapselpolysackariden och proteinet.
2. Förfarande enligt patentkrav 1, kännetecknat av att ca 5-50 %, företrädesvis ca 5-35 %, heist ca 5-10 %, av varje polysackarids sialsyrarester oxideras för att bilda aldehydgrupper som förmär anslutas till protein. 15
3. Förfarande enligt patentkrav 2, kännetecknat av att polysackariden är GBS typ II och att ca 7 % av varje polysackarids sialsyrarester oxideras för att bilda aldehydgrupper som förmär anslutas till protein. 20
4. Förfarande enligt patentkrav 1, kännetecknat av att ca 5-50 %, företrädesvis ca 5-25 %, heist ca 5-10 %, av varje polysackarids sialsyrarester binds kovalent tili protein.
5. Förfarande enligt patentkrav 4, kännetecknat av att polysackariden är GBS . · 25 typ II och att ca 5 % av varje polysackarids sialsyrarester binds kovalent till protein.
6. Förfarande enligt patentkrav 1, kännetecknat av att polysackariden är GBS typ V och att ca 25 % av varje polysackarids terminala sialsyrarester binds kovalent till protein. 30 # · * · 4
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94997092A | 1992-09-24 | 1992-09-24 | |
US94997092 | 1992-09-24 | ||
US12555693A | 1993-09-23 | 1993-09-23 | |
US12555693 | 1993-09-23 | ||
US9309056 | 1993-09-24 | ||
PCT/US1993/009056 WO1994006467A1 (en) | 1992-09-24 | 1993-09-24 | Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines |
Publications (3)
Publication Number | Publication Date |
---|---|
FI951412A0 FI951412A0 (sv) | 1995-03-24 |
FI951412A FI951412A (sv) | 1995-05-24 |
FI110993B true FI110993B (sv) | 2003-05-15 |
Family
ID=26823688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI951412A FI110993B (sv) | 1992-09-24 | 1995-03-24 | Förfarande för tillverkning av polysakkarid-proteinkonjugat av B-gruppens streptokock typer II och V |
Country Status (16)
Country | Link |
---|---|
US (2) | US5795580A (sv) |
EP (1) | EP0667787B1 (sv) |
JP (3) | JP4163251B2 (sv) |
KR (1) | KR100293017B1 (sv) |
AT (1) | ATE203167T1 (sv) |
AU (1) | AU690525B2 (sv) |
CA (1) | CA2145397C (sv) |
DE (1) | DE69330464T2 (sv) |
DK (1) | DK0667787T3 (sv) |
ES (1) | ES2160601T3 (sv) |
FI (1) | FI110993B (sv) |
GR (1) | GR3036928T3 (sv) |
IL (1) | IL107103A (sv) |
NO (2) | NO319569B1 (sv) |
NZ (2) | NZ248766A (sv) |
PT (1) | PT667787E (sv) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69719677T2 (de) * | 1996-11-18 | 2003-09-18 | Japan Storage Battery Co Ltd | Positivelektrode für Lithiumbatterie und Lithiumbatterie |
DE69940338D1 (de) * | 1998-02-05 | 2009-03-12 | Jackson H M Found Military Med | Vereinfachte methode zur entfernung von freiem protein während der herstellung von protein-polysaccharid-konjugaten und impfstoffen unter verwendung von medien mit limitierter durchlässigkeit |
US7018637B2 (en) * | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
EP1810978B1 (en) | 2000-08-08 | 2013-02-13 | St. Jude Children's Research Hospital | Group B streptococcus polypeptides nucleic acids and therapeutic composition and vaccines thereof |
SV2003000753A (es) * | 2000-12-05 | 2003-06-16 | Brigham & Womens Hospital | Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico |
US20030185858A1 (en) * | 2001-08-15 | 2003-10-02 | Birkett Ashley J. | Immunogenic HBc chimer particles stabilized with an N-terminal cysteine |
US7534442B2 (en) * | 2001-08-21 | 2009-05-19 | The Brigham And Women's Hospital, Inc. | Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid |
AU2003257003A1 (en) * | 2002-07-30 | 2004-02-16 | Baxter Healthcare S.A. | Chimeric multivalent polysaccharide conjugate vaccines |
EP1638581A2 (en) | 2003-03-31 | 2006-03-29 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
CA2530363C (en) * | 2003-06-23 | 2013-05-07 | Baxter International Inc. | Carrier proteins for vaccines |
CA2586058A1 (en) * | 2004-11-01 | 2006-05-11 | Dennis L. Kasper | Modified streptococcal polysaccharides and uses thereof |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
US8206726B2 (en) * | 2006-02-06 | 2012-06-26 | The Brigham And Women's Hospital, Inc. | Zwitterionic polysaccharides for promotion of immune system maturation and health |
GB201101665D0 (en) * | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
JP6273200B2 (ja) | 2011-07-12 | 2018-01-31 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 脂質含有psa組成物、その単離の方法および使用の方法 |
WO2014053612A1 (en) | 2012-10-03 | 2014-04-10 | Novartis Ag | Immunogenic composition |
SG11201708242YA (en) * | 2015-05-04 | 2017-11-29 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
WO2017031431A1 (en) | 2015-08-19 | 2017-02-23 | President And Fellows Of Harvard College | Lipidated psa compositions and methods |
WO2018014012A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
EP3965826A1 (en) * | 2019-05-10 | 2022-03-16 | GlaxoSmithKline Biologicals S.A. | Conjugate production |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4324887A (en) * | 1978-08-16 | 1982-04-13 | President And Fellows Of Harvard College | Type II group B Streptococci polysaccharide |
US4207414A (en) * | 1978-08-16 | 1980-06-10 | President And Fellows Of Harvard College | Polysaccharide antigens |
PT72812B (en) * | 1980-04-14 | 1983-02-16 | Merck & Co Inc | Process for preparing group b streptococcal capsular polysccha-rides |
US4438261A (en) * | 1980-05-19 | 1984-03-20 | Riker Laboratories, Inc. | Anticoagulant substance |
US4367221A (en) * | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Immunization against Group B streptococci |
US4356263A (en) * | 1980-06-09 | 1982-10-26 | President And Fellows Of Harvard College | Method of making a polysaccharide vaccine |
US4367222A (en) * | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Immune globulin specific to Group B streptococci |
US4367223A (en) * | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Vaccine against Group B streptococci |
US4284537A (en) * | 1980-07-03 | 1981-08-18 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate of streptococcal M protein peptide vaccine |
US4425330A (en) * | 1981-05-20 | 1984-01-10 | Cornell Research Foundation, Inc. | Bovine mastitis vaccine and method for detecting efficacy thereof |
US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4619828A (en) * | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
US4757134A (en) * | 1982-12-02 | 1988-07-12 | The Rockefeller University | IgA binding protein |
ATE70308T1 (de) * | 1984-09-12 | 1991-12-15 | Chiron Corp | Hybridpartikel-immunogene. |
FR2581877B1 (fr) * | 1985-05-14 | 1987-12-18 | Louvain Universite Catholique | Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries |
US5302386A (en) * | 1986-04-16 | 1994-04-12 | Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines and methods of manufacture |
WO1987006267A1 (en) * | 1986-04-16 | 1987-10-22 | The Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines, and methods of manufacture |
NZ225372A (en) * | 1987-07-17 | 1991-04-26 | Xoma Corp | Immunotoxin composition comprising purified ricin-a-chain species |
IL95578A (en) * | 1989-09-15 | 1998-08-16 | Gen Hospital Corp | A vaccine made from polysaccharide and protein |
EP0504202B1 (en) * | 1989-12-14 | 1995-05-03 | National Research Council Of Canada | Improved meningococcal polysaccharide conjugate vaccine |
FR2682388B1 (fr) * | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal. |
-
1993
- 1993-09-24 EP EP93922357A patent/EP0667787B1/en not_active Expired - Lifetime
- 1993-09-24 AU AU51378/93A patent/AU690525B2/en not_active Ceased
- 1993-09-24 AT AT93922357T patent/ATE203167T1/de not_active IP Right Cessation
- 1993-09-24 IL IL10710393A patent/IL107103A/en not_active IP Right Cessation
- 1993-09-24 NZ NZ248766A patent/NZ248766A/en not_active IP Right Cessation
- 1993-09-24 DK DK93922357T patent/DK0667787T3/da active
- 1993-09-24 NZ NZ299249A patent/NZ299249A/xx not_active IP Right Cessation
- 1993-09-24 KR KR1019950701137A patent/KR100293017B1/ko not_active IP Right Cessation
- 1993-09-24 JP JP50844194A patent/JP4163251B2/ja not_active Expired - Fee Related
- 1993-09-24 PT PT93922357T patent/PT667787E/pt unknown
- 1993-09-24 DE DE69330464T patent/DE69330464T2/de not_active Expired - Fee Related
- 1993-09-24 CA CA002145397A patent/CA2145397C/en not_active Expired - Fee Related
- 1993-09-24 ES ES93922357T patent/ES2160601T3/es not_active Expired - Lifetime
-
1995
- 1995-03-23 NO NO19951109A patent/NO319569B1/no not_active IP Right Cessation
- 1995-03-24 FI FI951412A patent/FI110993B/sv active
- 1995-03-24 NO NO951152A patent/NO951152D0/no unknown
- 1995-06-07 US US08/483,647 patent/US5795580A/en not_active Expired - Lifetime
-
1998
- 1998-02-13 US US09/023,526 patent/US5993825A/en not_active Expired - Fee Related
-
2001
- 2001-10-18 GR GR20010401795T patent/GR3036928T3/el not_active IP Right Cessation
-
2005
- 2005-07-05 JP JP2005196902A patent/JP4308174B2/ja not_active Expired - Fee Related
-
2009
- 2009-03-09 JP JP2009055767A patent/JP2009132727A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL107103A0 (en) | 1994-08-26 |
FI951412A0 (sv) | 1995-03-24 |
JP2009132727A (ja) | 2009-06-18 |
CA2145397A1 (en) | 1994-03-31 |
NO951109D0 (no) | 1995-03-23 |
JP4308174B2 (ja) | 2009-08-05 |
KR950703361A (ko) | 1995-09-20 |
JPH08501563A (ja) | 1996-02-20 |
NZ299249A (en) | 2000-08-25 |
JP2005306884A (ja) | 2005-11-04 |
AU5137893A (en) | 1994-04-12 |
NZ248766A (en) | 1996-11-26 |
GR3036928T3 (en) | 2002-01-31 |
AU690525B2 (en) | 1998-04-30 |
NO951109L (no) | 1995-05-22 |
FI951412A (sv) | 1995-05-24 |
DK0667787T3 (da) | 2001-10-29 |
ATE203167T1 (de) | 2001-08-15 |
DE69330464D1 (en) | 2001-08-23 |
NO319569B1 (no) | 2005-08-29 |
US5795580A (en) | 1998-08-18 |
US5993825A (en) | 1999-11-30 |
IL107103A (en) | 2001-03-19 |
PT667787E (pt) | 2001-10-31 |
KR100293017B1 (ko) | 2001-09-17 |
NO951152D0 (no) | 1995-03-24 |
CA2145397C (en) | 2007-10-30 |
ES2160601T3 (es) | 2001-11-16 |
DE69330464T2 (de) | 2001-11-08 |
EP0667787B1 (en) | 2001-07-18 |
JP4163251B2 (ja) | 2008-10-08 |
EP0667787A1 (en) | 1995-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI110993B (sv) | Förfarande för tillverkning av polysakkarid-proteinkonjugat av B-gruppens streptokock typer II och V | |
Paoletti et al. | Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine | |
Paoletti et al. | Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine | |
Wessels et al. | Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine | |
US7332173B2 (en) | Group A streptococcal polysaccharide immunogenic compositions and methods | |
JP2736248B2 (ja) | 莢膜ポリマーフラグメントの製造方法 | |
US4673574A (en) | Immunogenic conjugates | |
US4761283A (en) | Immunogenic conjugates | |
EP0598818B1 (en) | Escherichia coli o-polysaccharide-protein conjugate vaccine | |
US7449189B2 (en) | Glycoconjugate vaccines for use in immune-compromised populations | |
US5843461A (en) | Group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccines | |
CA2101648C (en) | Polysaccharide-protein conjugates | |
US4762713A (en) | Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers |